LOGIN  |  REGISTER
Astria Therapeutics
Recursion

PACS Group to Announce First Quarter 2024 Financial Results

May 06, 2024 | Last Trade: US$10.62 0.44 -3.98

FARMINGTON, Utah / May 06, 2024 / Business Wire / PACS Group, Inc. (NYSE: PACS) (“PACS Group” or the “Company”), today announced that it will release its first quarter 2024 financial results after market close on Monday, May 13, 2024. Management will host a call the following day, Tuesday, May 14, 2024, at 4:00 p.m. Eastern Time to discuss the financial results and related information.

PACS Group invites current and prospective investors to listen to the call via webcast by going to the Investors section of the PACS Group website at https://IR.pacs.com. A recording of the call will be available for replay via the website for 30 days following the call. The Company’s press releases, SEC filings, public conference calls, webcasts and website frequently disclose information that may be material to investors, and the Company encourages investors and others interested in the Company to regularly monitor those outlets for important Company information.

About PACS Group

PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate over 200 post-acute care facilities across nine states serving over 22,000 patients daily.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page